Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jan;13(1):56-82.
doi: 10.1631/jzus.B1100120.

New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy

Jing Tong  1 , You-wei Wang, Yuan-an Lu
Affiliations
Review

New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy

Jing Tong et al. J Zhejiang Univ Sci B. 2012 Jan.

Abstract

Infection with hepatitis C virus (HCV) affects approximately 170 million people worldwide. However, no vaccine or immunoglobulin is currently available for the prevention of HCV infection. The standard of care (SOC) involving pegylated interferon-α (PEG-IFN α) plus ribavirin (RBV) for 48 weeks results in a sustained virologic response in less than 50% of patients with chronic hepatitis C genotype 1, the most prevalent type of HCV in North America and Europe. Recently, reliable in vitro culture systems have been developed for accelerating antiviral therapy research, and many new specifically targeted antiviral therapies for hepatitis C (STAT-C) and treatment strategies are being evaluated in clinical trials. These new antiviral agents are expected to improve present treatment significantly and may potentially shorten treatment duration. The aim of this review is to summarize the current developments in new anti-HCV drugs.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Ali S, Leveque V, Le Pogam S, Ma H, Philipp F, Inocencio N, Smith M, Alker A, Kang H, Najera I, et al. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob Agents Chemother. 2008;52(12):4356–4369. doi: 10.1128/AAC.00444-08. - DOI - PMC - PubMed
    1. Bavisotto L, Wang CC, Jacobson IM, Marcellin P, Zeuzem S, Lawitz EJ, Lunde M, Sereni P, O′Brien C, Oldach DW, et al. Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected subjects. Hepatology. 2007;46(4):255A.
    1. Bedard J, Nicolas O, Bilimoria D, L′Heureux L, Fex P, David M, Chan L. Identification and characterization of VCH-222, a novel potent and selective non-nucleoside HCV polymerase inhibitor. J Hepatol. 2009;50(S1):S340. doi: 10.1016/S0168-8278(09)60937-5. - DOI
    1. Boerner J, Ma S, Compton T, Lin K. NIM811, a cyclophilin inhibitor, and NM107, an HCV polymerase inhibitor, synergistically inhibits HCV replication and suppresses the emergence of resistance in vitro. Antivir Res. 2007;74(3):A57. doi: 10.1016/j.antiviral.2007.01.081. - DOI
    1. Brown NA. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues. Expert Opin Inv Drugs. 2009;18(6):709–725. doi: 10.1517/13543780902854194. - DOI - PubMed

Publication types

MeSH terms